(Q33383165)

26 July 2017

Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

4

Carson BS

1 reference

26 July 2017

5

Wharam MD

1 reference

26 July 2017

Corden BJ

1

1 reference

26 July 2017

Strauss LC

2

1 reference

26 July 2017

Killmond T

3

1 reference

26 July 2017

Kumar AJ

6

1 reference

26 July 2017

Piantadosi S

7

1 reference

26 July 2017

Robb PA

8

1 reference

26 July 2017

Phillips PC

9

1 reference

26 July 2017

1 August 1991

1 reference

Journal of Neuro-Oncology

26 July 2017

1 reference

26 July 2017

11

1 reference

26 July 2017

1

1 reference

26 July 2017

57-63

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00166998

26 July 2017

0 references

cites work

Cisplatin therapy in recurrent childhood brain tumors.

1 reference

12 December 2020

Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

1 reference

12 December 2020

Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study

1 reference

12 December 2020

A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group.

1 reference

12 December 2020

Cisplatin plus cytosine arabinoside in adults with malignant gliomas

1 reference

12 December 2020

Interaction of etoposide and cisplatin in an in vitro tumor model

1 reference

12 December 2020

Letter: neuropathy due to cytosine arabinoside

1 reference

12 December 2020

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1 reference

12 December 2020

Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study.

1 reference

12 December 2020

Enhanced cis-platinum neurotoxicity in pediatric patients with brain tumors.

1 reference

12 December 2020

Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents

1 reference

12 December 2020

Peripheral sensory neuropathy and cisplatin chemotherapy

1 reference

12 December 2020

Cisplatin in the treatment of recurrent childhood primary brain tumors.

1 reference

12 December 2020

Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials.

1 reference

12 December 2020

Evaluation of cisplatin in children with recurrent brain tumors.

1 reference

12 December 2020

Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia

1 reference

12 December 2020

Intensive chemotherapy including cisplatin with or without etoposide for children with soft-tissue sarcomas

1 reference

12 December 2020

Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00166998

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference